Boston Scientific nabs French coverage
This article was originally published in The Gray Sheet
Executive Summary
The French government will pay for Taxus Liberté after the drug-eluting stent received reimbursement approval on Feb. 15. The firm notes that the paclitaxel-eluting stent will now be available to patients at both private and public hospitals in France. The device was CE marked in September 2005. According to the firm, France was slow to adopt and reimburse the original Taxus stent (1"The Gray Sheet" Feb. 9, 2004, p. 20)...
You may also be interested in...
Boston Scientific Taxus Inventory Of 150,000 Planned For U.S. Launch
Boston Scientific projects a 60% U.S. drug-eluting stent market penetration "right out of the gate" for its soon-to-be-launched Taxus, according to Senior VP and Cardiovascular Group President Paul LaViolette
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.